Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of treatment that doctors hope will work against many types of tumors.

Merck and Moderna just proved their cancer vaccine works, and the ripple effects reach far beyond either company.

Moderna's cancer treatment could treat more than just Melanoma, though the stock's momentum is already stalling. Should you still buy the dip?

The 135-year-old drugmaker, founded in 1891 and now based in Rahway, New Jersey, announced a milestone that oncologists have chased for years: a personalized cancer treatment that worked in a large, controlled study. Investors took notice, sending the blue-chip healthcare stock higher by 12.6% on Aug. 19.

Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares have crashed 20% as of 12:00 PM ET on Thursday after delivering one of the biotech sector’s most extraordinary single-day moves of 2026. CNBC co-anchor Andrew Ross Sorkin told viewers that Moderna’s Phase 3 results for its experimental cancer vaccine sent the stock soaring 177% on Wednesday,

A new treatment approach for people with early-stage rectal cancer could change the way the disease is treated. Results from the international STAR-TREC trial

Bianna speaks to Dr. Hussein Tawbi, oncologist and researcher at the University of Texas MD Anderson Cancer Center who leads the Phase 3 melanoma vaccine trial, and Dr. Ezekiel Emanuel, former Obama White House health policy adviser,

Weizmann Institute of Science and Rowan University researchers show that repair enzymes fail to fix gene structures of certain shapes, in discovery that may lead to new therapies The post Breakthrough Israeli cancer study finds mutations break DNA when it doesn’t bend appeared first on The Times of Israel.